Tango Therapeutics, INC DEF 14A proxy statements

Tango Therapeutics has scheduled its 2026 Annual Meeting of Stockholders for June 4, 2026, to elect directors, ratify auditors, and conduct an advisory vote on executive compensation.

Tango Therapeutics seeks stockholder approval to double its authorized common stock, providing flexibility for future capital raises and strategic initiatives.

Tango Therapeutics is holding its 2025 Annual Meeting, seeking shareholder votes on key proposals including the election of a director, ratification of the auditor, an increase in authorized shares, and executive compensation.

Tango Therapeutics is holding its 2025 Annual Meeting of Stockholders to vote on key proposals, including increasing authorized common stock and executive compensation.

Tango Therapeutics is holding its 2024 Annual Meeting of Stockholders virtually on June 5, 2024, to vote on director elections, auditor ratification, and an amendment to limit officer liability.